Although TRAIL is not reportedly associated with CDDP sensitivity, multiple lines of evidence show that CDDP enhances susceptibility to TRAIL-mediated apoptosis in various malignancies, including esophageal, lung and bladder cancers [43–46]. This evidence concerns the gene TNFSF10 and urinary bladder carcinoma.